Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, announced that it will provide student conference sponsorship for a second year to the Future of Hearing Healthcare Conference, which will allow up to 75 audiology graduate students to attend the event at no cost.
The conference sponsorship is open to any students currently pursuing a graduate-level degree (Master’s or Doctorate) in audiology or related discipline.
The virtual conference, hosted by Hearing Health & Technology Matters (HHTM), will take place virtually over three days, from May 24-May 26, with a focus on the developments and technologies shaping hearing healthcare over the coming decade.
Kevin Franck, PhD, SVP of Strategic Marketing and New Product Planning, will be co-presenting a session during the conference alongside Frequency’s Chief Development Officer, Carl LeBel, PhD: “Potential New Therapies and Clinical Trial Opportunities for Adult-Onset Acquired Sensorineural Hearing Loss.”
Attendees participating in this year’s event can earn CEUs (up to 13 contact hours) from experts in clinical audiology, neuroscience, hearing aids, consumer technology, and more.
Among the topics being addressed during the conference:
- Hair Cell Regeneration;
- Clinical and Practice Differentiation;
- Forensic Audiology;
- Haptic Tech for Hearing Loss;
- Balance & Vestibular Care;
- Assistive Technologies;
- Cerumen Removal;
- Going Beyond the Hearing Aid.
Attendees will have access to the sessions for up to 30 days. Individuals interested to learn more about the event, please visit: https://hearinghealthmatters.org/fhh-conference/.
Tickets are available at an early-bird rate of $99, if purchased by May 6. Tickets are available here: https://www.accelevents.com/e/futureofhearinghealthcare22.
The first 100 registrants will also receive a free copy of Brian Taylor’s upcoming book, Indispensable: What Four Acclaimed Late Audiologists Can Teach Us About the Value of Customization in the Era of Self-directed Care, set to be released in late May 2022.
About Frequency Therapeutics
Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore function – first in hearing loss and then in multiple sclerosis (MS) – by developing therapeutics that activate a person’s innate regenerative potential within the body through the activation of progenitor cells to restore lost function. Frequency’s hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for SNHL.
HHTM is an organization dedicated to bridging the knowledge gaps in treating hearing loss by providing timely information and lively insights to anyone who cares about hearing loss. Readers and contributors are drawn from many sectors of the hearing field, including practitioners, researchers, manufacturers, educators, and, importantly, consumers with hearing loss and those who love them.
Source: Frequency Therapeutics, HHTM